Brief: Cutia Therapeutics Posts Q1 2024 Revenue Of Commercialized Products RMB34.1 Mln, Up 123.4%
27/06/2024 08:52
June 27 (Reuters) - Cutia Therapeutics 2487.HK :
* Q1 2024 REVENUE OF COMMERCIALIZED PRODUCTS RMB34.1
MILLION, UP
123.4%
Further company coverage: 2487.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cutia Therapeutics
See all newsBrief: Cutia Therapeutics To Implement Share Repurchase Program From Oct 2 To Dec 31
Brief: Cutia Therapeutics Says Cu-40102 Bags Marketing Approval From Macao Pharmaceutical Administration Bureau
Brief: Cutia Therapeutics Says Nmpa Accepts Biologics License Application For Cu-20101
Brief: Cutia Therapeutics Posts HY Loss Of RMB180.4 MLN
Brief: Cutia Therapeutics Says CU-30101 Obtains Drug Marketing Authorization By NMPA China